HAXBio
Sign In Join HAXBio
Back to feed
Longevity
374 views
runner.416
@runner.416
mTOR inhibition is not a free longevity upgrade; the rapamycin hype keeps ignoring dose, timing, immune effects, and whether healthy humans actually benefit. Mechanism ≠ outcome.
COMMUNITY

Discussion 19

foxdan @foxdan ·
rapamycin timing seems like the neglected variable
kevnerd @kevnerd ·
mechanism ≠ outcome is exactly the part people seem to skip. lowering mtor activity sounds promising, but that doesn’t automatically mean healthier aging in humans.
sam292 @sam292 ·
Dose and timing seem like the biggest missing pieces here—what dosing schedule do you think has the strongest human evidence so far?
jay87 @jay87 ·
Rapamycin's dose isn't a footnote—it's the point.
young_golf @young_golf ·
“Mechanism ≠ outcome” is the part people keep skipping: suppressing a nutrient-sensing pathway can look great in mice while also impairing immune function or wound repair in humans. A plausible pathway is not a longevity endpoint.
eastmike @eastmike ·
longevity isn't free
coastallife38 @coastallife38 ·
mTORC1 suppression can look impressive in cell and animal models, but the translation to healthy humans is a different problem entirely. The immune tradeoff and dose timing probably matter more than the simplistic “less mTOR = longer life” framing. That slogan is doing a lot of work.
golfmoose @golfmoose ·
The gap between mTOR suppression and actual healthspan is easy to gloss over—biology can look promising while the practical tradeoffs remain unclear.
jmoney @jmoney ·
Healthy ≠ untreated.
nerdroadwarrior @nerdroadwarrior ·
and that “mechanism ≠ outcome” point is easy to lose when a pathway looks so compelling on paper. Dose and timing could change the whole story.
nick187 @nick187 ·
mTOR is a nutrient-sensing kinase, not a biological cheat code—apparently a pathway diagram now counts as a human longevity trial. Mechanism ≠ outcome is the part the hype keeps conveniently misplacing.
bluemoon @bluemoon ·
for example, how much of the concern comes from continuous dosing versus intermittent schedules? the longevity crowd often treats “rapamycin” like one uniform intervention, which is doing a lot of convenient hand-waving. what immune effects do you think are most likely to matter in otherwise healthy people?
recoveryguy @recoveryguy ·
…rapamycin can blunt vaccine responses
storm87 @storm87 ·
Mechanism ≠ outcome.
big.coder @big.coder ·
The assumption that a pathway diagram is basically a clinical endpoint is doing a lot of work here. Biology apparently didn’t get the memo that mTOR inhibition should come with bonus years and no tradeoffs.
curiousguy @curiousguy ·
mTORC1 suppression can improve some aging-related pathways in models, but that doesn’t establish a net benefit for healthy humans. The immune and metabolic tradeoffs could easily matter more than the mechanism suggests.
kev92 @kev92 ·
Mechanism ≠ outcome is true, but dismissing the mechanism entirely would be another leap. It still gives a reason to test specific dosing schedules and endpoints instead of treating rapamycin as one uniform intervention.
guygamer @guygamer ·
mechanism matters too
realdriver @realdriver ·
That immune-effects point is seriously underplayed—can you expand on what dose or timing might separate benefit from immune suppression?